Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Autonomix Medical, Inc. (AMIX)
USD5.30
+0.11 (+2.12%)
US NASDAQ Healthcare Medical - Devices
Address
21 Waterway Avenue 77380
The Woodlands, TX, US
The Woodlands, TX, US
CEO
Bradley A. Hauser
Website
autonomix.com
IPO
2024-01-29
CIK 1617867 ISIN US05330T3041
Description
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD5.30
+0.11 (+2.12%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
38.7K
Beta
-1.41
Float Shares
4.84M
Free Float %
94.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.61% | +2.04% | +17.61% | -8.86% | -62.62% | -27.27% | -75.76% | -99.61% | -99.61% | -99.61% | -99.61% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
5.30
DCF (Unlevered)
0.09
-98.3%
DCF (Levered)
0.10
-98.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-18.00
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%—
-
EPS growth Medical - Devices: +28.5%+64.1% ★ Q1'26: +87.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%—
-
EBIT margin Medical - Devices: +6.2%—
-
ROIC Medical - Devices: +3.3%— Q1'26: +987.2% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+3,986.5% Q1'26: +3,985.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2025 actual |
Mar 2026 1 EPS Ana. |
Mar 2027 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
|
—
— – —
|
—
— – —
|
900.0K
900.0K – 900.0K
|
8.22M
8.22M – 8.22M
+813.3% YoY
|
24.59M
24.59M – 24.59M
+199.1% YoY
|
| EBITDA |
-11.05M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-11.23M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-11.41M
est: -6.98M (-63.4%)
|
-169.59M
-169.59M – -169.59M
-2,328.1% YoY
|
-65.67M
-65.67M – -65.67M
+61.3% YoY
|
-146.50M
-146.50M – -146.50M
-123.1% YoY
|
-127.01M
-127.01M – -127.01M
+13.3% YoY
|
-75.05M
-75.05M – -75.05M
+40.9% YoY
|
| SGA |
6.86M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-6.46
est: -3.96 (-63.3%)
|
-2.35
-2.35 – -2.35
+40.6% YoY
|
-0.91
-0.91 – -0.91
+61.3% YoY
|
-2.03
-2.03 – -2.03
-123.1% YoY
|
-1.76
-1.76 – -1.76
+13.3% YoY
|
-1.04
-1.04 – -1.04
+40.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-26 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-14 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-13 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-12 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
15
Total invested
144.8K
Insider transactions (90d)
0
Beneficial owners (>5%)
12
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Walter V. Klemp | 3.02M | 16.00% | 3.02M | — | 3.02M | — | IN | — | 2024-02-15 | ↗ |
| 2 | BioStar Ventures III, L.P. | 2.42M | 10.50% | 2.42M | — | 2.42M | — | PN | United States of America | 2024-10-07 | ↗ |
| 3 | Landy Toth | 2.03M | 10.80% | 2.03M | — | 2.03M | — | IN | United States | 2024-02-26 | ↗ |
| 4 | Jonathan Juchno | 764.5K | 9.90% | — | 764.5K | — | — | IN | Delaware | 2024-12-03 | ↗ |
| 5 | C/M Capital Partners, LP | 611.6K | 9.90% | — | 611.6K | — | — | PN | Delaware | 2024-12-03 | ↗ |
| 6 | Thomas Walsh | 611.6K | 9.90% | — | 611.6K | — | — | IN | Delaware | 2024-12-03 | ↗ |
| 7 | C/M Capital Master Fund, LP | 305.8K | 9.99% | — | 305.8K | — | — | PN | Delaware | 2024-12-03 | ↗ |
| 8 | Cavalry Fund I LP | 305.8K | 9.99% | — | 305.8K | — | — | PN | Delaware | 2024-12-03 | ↗ |
| 9 | CVI Investments, Inc. | 194.0K | 9.90% | — | 194.0K | — | 194.0K | CO | Cayman Islands | 2024-11-27 | ↗ |
| 10 | Heights Capital Management, Inc. | 194.0K | 9.90% | — | 194.0K | — | 194.0K | CO | Cayman Islands | 2024-11-27 | ↗ |
| 11 | Mercer Street Capital Partners, LLC | 152.9K | 7.10% | — | 152.9K | — | — | OO | Delaware | 2024-12-03 | ↗ |
| 12 | Mercer Street Global Opportunity Fund, LLC | 152.9K | 7.10% | — | 152.9K | — | — | OO | Delaware | 2024-12-03 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
15
-2 vs prev Q
New positions
2
Closed positions
4
Increased
4
Reduced
3
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 175.6K +152.1K (+647.1%) | 68.5K +55.6K (+429.9%) | 1.96% +1.699 pp | 0.00% +0.000 pp | USD0.47 -17.0% | 4 qtrs — |
| 2 | MARINER, LLC | 52.9K -233.0 (-0.4%) | 25.9K -594.0 (-2.2%) | 0.59% -0.003 pp | 0.00% +0.000 pp | USD3.76 -89.6% | 6 qtrs — |
| 3 | UBS GROUP AG | 33.5K +33.4K (+26,275.6%) | 13.1K +13.0K (+18,562.9%) | 0.37% +0.373 pp | 0.00% +0.000 pp | USD0.40 -2.5% | 6 qtrs — |
| 4 | LPL FINANCIAL LLC | 31.4K +— (+0.0%) | 12.3K -5.0K (-29.1%) | 0.35% +0.000 pp | 0.00% +0.000 pp | USD0.55 -29.1% | 2 qtrs — |
| 5 | BANK OF MONTREAL /CAN/ | 25.0K +— (+0.0%) | 9.8K -4.0K (-29.1%) | 0.28% +0.000 pp | 0.00% +0.000 pp | USD1.08 -63.9% | 3 qtrs — |
| 6 | IKARIAN CAPITAL, LLC | 18.7K +— (+0.0%) | 7.3K -3.0K (-29.1%) | 0.21% +0.000 pp | 0.00% 0.000 pp | USD3.76 -89.6% | 6 qtrs — |
| 7 | VIRTU FINANCIAL LLC | 12.9K +12.9K (+100.0%) | 5.0K +5.0K (+100.0%) | 0.14% +0.144 pp | 0.00% +0.000 pp | USD0.39 +0.0% | 1 qtrs NEW |
| 8 | TOWER RESEARCH CAPITAL LLC (TRC) | 5.8K -8.0 (-0.1%) | 2.3K -938.0 (-29.2%) | 0.07% 0.000 pp | 0.00% +0.000 pp | USD1.65 -76.4% | 6 qtrs — |
| 9 | PNC FINANCIAL SERVICES GROUP, INC. | 1.6K +— (+0.0%) | 619.00 -254.0 (-29.1%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD3.76 -89.6% | 6 qtrs — |
| 10 | INVESTORS RESEARCH CORP | 200.00 -20.0 (-9.1%) | 78.00 -43.0 (-35.5%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.77 -78.0% | 6 qtrs — |
| 11 | — | 10.00 +— (+0.0%) | 4.00 -2.0 (-33.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.50 -22.0% | 2 qtrs — |
| 12 | FARTHER FINANCE ADVISORS, LLC | 10.00 +10.0 (+100.0%) | 4.00 +4.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.30 +30.0% | 1 qtrs NEW |
| 13 | HARBOUR INVESTMENTS, INC. | 10.00 +— (+0.0%) | 4.00 -2.0 (-33.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.70 -89.5% | 6 qtrs — |
| 14 | SWAN CAPITAL LLC | 10.00 +— (+0.0%) | 4.00 -2.0 (-33.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.70 -89.5% | 6 qtrs — |
| 15 | NATIONAL BANK OF CANADA /FI/ | 7.00 +— (+0.0%) | 3.00 -1.0 (-25.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.71 -89.5% | 6 qtrs — |
| 16 | TWO SIGMA SECURITIES, LLC | — -10.9K (-100.0%) | — -6.0K (-100.0%) | 0.00% -0.121 pp | 0.00% -0.001 pp | USD— | 3 qtrs SOLD |
| 17 | BANK OF AMERICA CORP /DE/ | — -50.0 (-100.0%) | — -28.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
| 18 | ADVISOR GROUP HOLDINGS, INC. | — -10.0 (-100.0%) | — -5.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
2
Shares acquired
—
Shares disposed
32.7K
Cash buys
—
Cash sales
—
Net activity
-32,655
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-11 | Smith Trent N. | Officer | D-Return | D | Option (Right to buy) | 21,250 | 40.00 | 850.0K | 1,250 | D | ↗ |
| 2025-08-11 | KLEMP WALTER V | Director | D-Return | D | Option (Right to buy) | 8,773 | 26.56 | 233.0K | 1,250 | D | ↗ |
| 2025-08-11 | Hauser Bradley | Officer | D-Return | D | Option (Right to buy) | 45,000 | 27.00 | 1.22M | 0 | D | ↗ |
| 2025-08-11 | Capelli Christopher | Director | D-Return | D | Option (Right to buy) | 3,750 | 40.00 | 150.0K | 0 | D | ↗ |
| 2025-08-11 | Bisson Lori | Director | D-Return | D | Option (Right to buy) | 46,680 | 40.00 | 1.87M | 1,250 | D | ↗ |
| 2024-01-26 | Smith Trent N. | Officer | — | D | Option (right to buy) | 425,000 | 2.00 | 850.0K | 0 | — | ↗ |
| 2024-01-26 | KLEMP WALTER V | Director | — | D | Common Stock | 0 | 0.00 | — | 2,990,000 | — | ↗ |
| 2024-01-26 | Foster Jonathan P. | Director | — | D | Common Stock | 0 | 0.00 | — | 725,000 | — | ↗ |
| 2024-01-26 | Capelli Christopher | Director | — | D | Option (right to buy) | 75,000 | 2.00 | 150.0K | 0 | — | ↗ |
| 2023-10-11 | Smith Trent N. | Officer | — | D | Warrant (right to buy) | 25,000 | 1.00 | 25.0K | 0 | — | ↗ |
| 2023-10-09 | KLEMP WALTER V | Director | — | D | Warrant (right to buy) | 25,000 | 1.00 | 25.0K | 0 | — | ↗ |
| 2023-10-06 | Foster Jonathan P. | Director | — | D | Warrant (right to buy) | 6,250 | 1.00 | 6.3K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
5.15M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Brad Hauser - Chief Executive Officer and President | 356.3K | — | — | 1.10M | 202.4K | — | 1.66M | 66.40% | ↗ |
| 2 | 2025 | Lori Bisson - Executive Vice Chairman | 210.0K | — | — | 355.3K | 93.8K | — | 659.1K | 53.90% | ↗ |
| 3 | 2025 | Trent Smith - Chief Financial Officer | 295.0K | — | — | 214.8K | 108.3K | — | 618.1K | 34.75% | ↗ |
| 4 | 2025 | Dr. Robert Schwartz, Former Chief Executive Officer and current Chief Medical Officer | 100.0K | — | — | 247.9K | 33.3K | — | 381.1K | 65.04% | ↗ |
| 5 | 2025 | Walter Klemp - Executive Chair | 160.4K | — | — | 165.2K | — | — | 325.7K | 50.74% | ↗ |
| 6 | 2025 | Landy Toth - Chief Technology Officer | 147.9K | — | — | 165.2K | — | — | 313.2K | 52.77% | ↗ |
| 7 | 2024 | Lori Bisson - Executive Vice Chairman | 225.0K | — | — | 1.47M | 150.0K | 17.5K | 1.86M | 78.91% | ↗ |
| 8 | 2024 | Trent Smith - Chief Financial Officer | 159.4K | — | — | 673.8K | 74.3K | 18.1K | 925.5K | 72.80% | ↗ |
| 9 | 2024 | Walter Klemp - Executive Chair | 200.0K | — | — | — | — | — | 200.0K | 0.00% | ↗ |
| 10 | 2024 | Landy Toth - Chief Technology Officer | 187.5K | — | — | — | — | — | 187.5K | 0.00% | ↗ |
| 11 | 2024 | Dr. Robert Schwartz, Former Chief Executive Officer and current Chief Medical Officer | 100.0K | — | — | — | 35.0K | — | 135.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bradley Hauser | Chief Executive Officer & President | 653.0K | male |
| Trent N. Smith | Executive Vice President & Chief Financial Officer | 403.3K | male |
| Lori H. Bisson | Executive Vice Chairman | 303.8K | female |
| Walter V. Klemp | Executive Chairman | 160.4K | male |
| Landy Toth | Co-Founder & Chief Technology Officer | 147.9K | male |
| Robert Schwartz | Co-Founder & Chief Medical Officer | 133.3K | — |
| David A. Robins | Co-Founder & Director | 60.0K | male |
| Jennifer Cook | Chief Business Officer | — | female |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AMIX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
